Compare Fox Corp Class A (FOXA) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs Repligen Corporation Common Stock — how do they compare? Fox Corp Class A trades at $62.63 (market cap $24.93B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Fox Corp Class A is far larger — about 2.2× Repligen Corporation Common Stock's market cap, and Fox Corp Class A pays a 0.93% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class A for 35 Days and Repligen Corporation Common Stock for 0 Days on average.
| FOXA | RGEN | |
|---|---|---|
Market Cap | $24.93B | $11.14B |
Volume | 2,221,953 | 1,259,263 |
Sector | Media | Health |
52-Week High | $76.11 | $194.57 |
52-Week Low | $48.79 | $102.87 |
Typical Hold Time | 35 Days | 0 Days |
Enterprise Value | $28.30B | $11.02B |
Dividend Yield | 0.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fox Corporation (FOXA) trades at $62.50, down slightly by 0.14% with a bearish technical signal. The company shows strong fundamentals with revenue growth from $14.0B in 2024 to $16.3B in 2025 and consistent earnings beats. Analyst consensus is bullish with a $72.00 price target, though the pending $22B Roku acquisition faces DOJ scrutiny. Cash flow improved significantly to $1.03B net in 2025, while 2026 projections show potential pressure.
FOXA presents a compelling value opportunity with reasonable valuations (P/E 16.3) and strong profitability (ROE 14.29%). The Roku deal represents both growth potential and regulatory risk. With zero sell ratings and insider buying, institutional sentiment remains positive despite technical weakness. Key risks include integration challenges and advertising market volatility.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
